Inspiremd engages hart clinical consultants to conduct clinical trial for cguard carotid stent system in the united states

Tel aviv, israel, feb. 24, 2021 (globe newswire) -- inspiremd, inc. (nyse american: nspr), developer of the cguard™ embolic prevention system (eps) for the prevention of stroke caused by carotid artery disease, announced today that it has engaged hart clinical consultants (hcc), a leading contract research organization (cro) to conduct the clinical trial for its cguard carotid stent system in the united states.
NSPR Ratings Summary
NSPR Quant Ranking